KR20180109327A - Device and method for drug action management - Google Patents

Device and method for drug action management Download PDF

Info

Publication number
KR20180109327A
KR20180109327A KR1020170038755A KR20170038755A KR20180109327A KR 20180109327 A KR20180109327 A KR 20180109327A KR 1020170038755 A KR1020170038755 A KR 1020170038755A KR 20170038755 A KR20170038755 A KR 20170038755A KR 20180109327 A KR20180109327 A KR 20180109327A
Authority
KR
South Korea
Prior art keywords
drug
unit
drug delivery
user
pattern
Prior art date
Application number
KR1020170038755A
Other languages
Korean (ko)
Other versions
KR102024273B1 (en
Inventor
남궁광
강민수
Original Assignee
주식회사 피에프디
강민수
남궁광
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 피에프디, 강민수, 남궁광 filed Critical 주식회사 피에프디
Priority to KR1020170038755A priority Critical patent/KR102024273B1/en
Publication of KR20180109327A publication Critical patent/KR20180109327A/en
Application granted granted Critical
Publication of KR102024273B1 publication Critical patent/KR102024273B1/en

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a drug action management device and method capable of tracking a drug delivery vehicle delivered to the affected part in real time so as to exhibit a therapeutic effect even with a small amount of drug and inducing drug action.

Figure pat00001

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention [0001] The present invention relates to a drug action management apparatus,

The present invention relates to an apparatus and method for managing a drug action.

Despite advances in modern medicine, patients suffering from diseases that require drug therapy or radiation therapy experience side effects such as cytotoxicity or side effects due to systemic administration of the drug, or mutation or death of normal cells by radiation therapy .

Thus, if drugs that are inevitably administered, such as contrast agents or therapeutic agents, can be accurately delivered to the desired target tissue, side effects on normal cells or normal tissues can be reduced. For this reason, studies on the targeting of drugs for diagnosis or treatment without side effects have been widely carried out.

Targeting of drug mainly uses a method of chemically or physically binding antibody or peptide, specific ligand, or polymer, etc., specific to a tissue or cell for the purpose of drug delivery to the drug. However, it is not always easy to bind antibodies, peptides, ligands and the like due to the physicochemical properties of the drug. In addition, when a binder or a stabilizer for chemical or physical binding is used, problems such as pharmacological properties and bio- May occur. Therefore, there is a continuing technical demand for a method of targeting a drug that does not cause such a problem.

Targeted drug delivery systems have been developed to minimize the side effects of other parts of the body by delivering the drug to the desired site and to maximize its efficiency, and are especially used to reduce the side effects of highly toxic anticancer drugs.

Attempted approaches for drug delivery systems include patch manufacturing techniques that deliver the drug through the skin, techniques for making microcapsules by lipids to be effective only in certain parts of the body, techniques for making non- Such as solid dispersion, gel, nanoparticles, liposomes, microemulsions, pellets, matrix tablets, osmotic pressure, and the like, have.

It is an object of the present invention to provide a drug action management apparatus and method capable of tracking drug trafficking to the affected part in real time and inducing drug action. The technical problem to be solved by this embodiment is not limited to the above-described technical problems, and other technical problems can be deduced from the following embodiments.

According to an aspect of the present invention, there is provided an information processing apparatus including: an operation unit for inputting an operation of a user; An ultrasonic irradiator for irradiating ultrasonic waves; A drug measurement unit capable of detecting the characteristics of the nanoparticles contained in the drug delivery system; A display unit capable of visually displaying a result of the drug measurement unit; A memory in which the characteristic effective range or pattern of the pathology or lesion, nanoparticle is stored; And a control unit responsive to a user operation or to control the ultrasound irradiation unit to emit ultrasonic waves when the result of the drug measurement unit corresponds to a characteristic effective range or pattern of nanoparticles stored in the memory / RTI >

According to preferred embodiments of the present invention, a communication unit for connecting to an external smart device via a network may be further included. Wherein the external smart device may include a display. The communication unit can support a short-range network connection with, for example, Bluetooth, Wi-Fi, and the like. The operation unit can select a measurement mode and a treatment mode according to a user's operation. The control unit can select the kind of the drug carrier and the kind of the nanoparticles and the control unit can control the operation of the ultrasound irradiation unit based on the kind of the drug carrier selected by the user and the kind of the nanoparticle through the operation unit .

According to another aspect of the present invention, there is provided an information processing apparatus including: an operation unit for inputting an operation of a user; A light irradiation unit for irradiating light; A drug measurement unit capable of detecting the characteristics of the nanoparticles contained in the drug delivery system; A display unit capable of visually displaying a result of the drug measurement unit; A memory in which the characteristic effective range or pattern of the pathology or lesion, nanoparticle is stored; And a control unit responsive to a user operation or to control the light irradiation unit to generate light heat when the result of the drug measurement unit corresponds to a characteristic effective range or pattern of nanoparticles stored in the memory / RTI > According to preferred embodiments of the present invention, both the ultrasound irradiating unit and the light irradiation unit can be included. The ultrasound irradiating unit and the light irradiation unit can be controlled to selectively or simultaneously operate according to the characteristics of the nanoparticles included in the drug delivery system or the structure of the drug delivery system.

According to still another aspect of the present invention, there is provided a method of measuring a drug delivery system, the method comprising: measuring a drug delivery system on a skin surface or a region above a lesion of a lesion based on characteristics of nanoparticles contained in the drug delivery system; Determining whether the drug delivery vehicle has a predetermined range or pattern and displaying the determined range or pattern; Controlling the drug carrier to be irradiated with ultrasonic waves or light heat in response to a user operation or when the measurement result of the drug carrier has a predetermined range or pattern.

The drug action management apparatus according to the embodiment of the present invention has a possibility to show a therapeutic effect even with a smaller amount of drugs.

FIG. 1 is a view for explaining the use of the drug action management apparatus according to a preferred embodiment of the present invention.
2 is a view for explaining a drug delivery device according to a preferred embodiment of the present invention.
3 is a block diagram for explaining a configuration of a drug action management apparatus according to a preferred embodiment of the present invention.
FIG. 4 is a flowchart illustrating a monitoring method using a drug action management apparatus according to a preferred embodiment of the present invention.
5 is a view for explaining a drug action management apparatus according to a preferred embodiment of the present invention.

DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, embodiments of the present invention will be described with reference to the accompanying drawings. It should be understood that the following embodiments of the present invention are only for embodying the present invention and do not limit or limit the scope of the present invention. It will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present invention as defined by the following claims.

As used herein, the terms " comprises " or " comprising ", etc. should not be construed as necessarily including the various elements or stages described in the specification, May not be included, or may be interpreted to include additional components or steps.

In addition, terms including ordinals such as 'first' or 'second' used in this specification can be used to describe various elements, but the elements should not be limited by the terms. The terms are used only for the purpose of distinguishing one component from another.

1 and 5 are views for explaining the use of the drug action management apparatus according to the preferred embodiment of the present invention.

Referring to FIG. 1, the apparatus for managing a pharmacological activity 100 according to a preferred embodiment of the present invention can control the delivery of a patient 130 to a foreign body 132 and / or the release of a drug at a foreign body 132 . When the user wishes to use the drug action management apparatus 100, the user turns on the drug action management apparatus 100 and places the drug action management apparatus 100 on or near the skin surface near the affected site 132.

According to one embodiment of the present invention, the drug action management apparatus 100 may include a display unit 102. [ The display unit 102 may be variously modified by a person having ordinary skill in the art such as an LED, an LCD, and a full touch screen.

According to another embodiment of the present invention, the display unit 102 of the drug substance management apparatus 100 may be omitted. In such a case, the drug action management apparatus 100 further includes a communication unit. The communication unit of the drug action management apparatus 100 may be connected to an external device through the network 120. [ The external device 110 may be, for example, an information processor that includes a display such as a smart phone 112, a pad terminal 114, and a computer 116. The connection with the external device 110 may be via a long-distance network such as a local area network such as Bluetooth, Wi-Fi, etc. and / or a cellular network.

The drug action management apparatus 100 according to embodiments of the present invention detects the drug delivery unit 200 near the affected part 132 or the affected part 132 of the patient 130 and outputs the result to the display unit 102 It can be displayed visually or through an external device connected through a network.

According to a preferred embodiment of the present invention, the operation unit is implemented by a plurality of buttons. Button 106 is for selecting a measurement mode and button 108 is for allowing the ultrasonic wave irradiating section and / or the light heat irradiating section to transmit ultrasound and / or light heat To input an operation of the user to be inspected.

According to another preferred embodiment of the present invention, the operation unit may be implemented as a single button. In this case, it is possible to input a user's operation signal by using the time of pressing the button, the pattern of pressing the button, the tokening method, or the like, alone or in combination, which will be obvious to those skilled in the art. According to another embodiment, when the drug action management apparatus includes a display unit such as a full touch screen, an operation button of the user can be input by displaying an operation button on the display unit as an icon or the like.

5, the drug action management apparatus 100 according to an exemplary embodiment of the present invention may be placed on or near the surface of the skin near the affected area 132, The outer shape of the device can be realized in the form of a curved surface.

An operation unit configured by one or a plurality of buttons may be implemented on the front side, and may further include a display unit. Although not shown in the drawings, an ultrasonic wave irradiation unit and / or a light irradiation unit may be located on the backside.

FIG. 2 is a view for explaining an example of a drug delivery device 200 that can be influenced by the drug action management apparatus according to the preferred embodiment of the present invention.

Referring to FIG. 2, the drug delivery device 200 can be used to minimize adverse effects or maximize the effect when delivering a drug such as an anti-cancer drug for treating the affected part 132 of the patient 130. According to one example, the drug delivery device 200 may be comprised of a drug 202, an antibody 204, nanoparticles 206. Drug 202 is for treatment of patient 130 and is surrounded by nanoparticles 206. That is, the drug 202 is coated with the nanoparticles 206. Therefore, the drug 202 does not act on the human body unless the coating of the nanoparticles 206 is peeled off. After the drug 202 reaches the lesion site, the user can use the drug action management apparatus 100 to remove the nanoparticle 206 coating to allow the drug to act on the lesion. By doing so, it is possible to prevent the drug from substantially affecting normal cells other than the affected part.

In the drug delivery embodiment shown in FIG. 2, the nanoparticle 206 coating consists of two parts, nanoparticle opening 206a and nanoparticle features 206b. The nanoparticle characteristic portion 206b may be made of a material exhibiting magnetism such as iron (Fe), nickel (Ni), or the like, so that magnetism, which is one of the characteristics of the nanoparticles, can be displayed. By measuring the magnetism, which is one of the characteristics of the nanoparticles, in the drug action management device 100, it is possible to measure to what extent the drug delivery device 200 has reached the affected part. The properties of the measurable nanoparticles are not limited to magnetism, but other properties that can be measured from the outside can be used.

The nanoparticle opening 206a is a portion that can be removed by ultrasonic waves and / or light heat according to the operation of the ultrasound irradiation unit and / or the light irradiation unit of the drug action management apparatus 100 according to the preferred embodiment of the present invention. The nanoparticle feature 206b may or may not be removed by ultrasonic and / or light heat. Further, the nanoparticles 206 can be discharged out of the body as time elapses.

According to one example of the drug delivery system shown in FIG. 2, the drug delivery system comprises an antibody 204. Antibody 204 is targeted to diseases such as, for example, cancer, and is formed on the outer surface of the nanoparticle 206 coating.

 3 is a block diagram for explaining a configuration of a drug action management apparatus according to a preferred embodiment of the present invention.

3, the drug action management apparatus 100 according to an exemplary embodiment of the present invention includes an ultrasound irradiation unit 302, a drug measurement unit 304, a memory 306, a control unit 308, and an operation unit 310 .

The ultrasound irradiating unit 302 irradiates ultrasound waves corresponding to the characteristic effective range or pattern of the nanoparticles 206 contained in the drug delivery system 200.

According to an embodiment of the present invention, the ultrasound irradiating unit 302 may include a trend ducer for generating and irradiating ultrasonic waves, and a driving driver for driving the transducer. In FIG. 3, the ultrasound irradiating unit 302 is exemplified. However, the ultraviolet irradiating unit and / or the ultrasound irradiating unit may be included according to the embodiment.

The drug measurement unit 304 may sense the characteristics of the nanoparticles 206 included in the drug delivery system 200. The nanoparticle 206 contains a drug 202 for treating the patient 130 and an antibody 204 having an affinity for a disease such as cancer is bound to the outside of the nanoparticle 206 .

According to one embodiment of the present invention, the nanoparticles 206 may be nanoparticles 206 that are responsive to ultrasound and / or light heat.

The memory 306 stores the pathology or lesion, the characteristic effective range or pattern of the nanoparticles.

According to an embodiment of the present invention, a characteristic validity range or a pattern, which is a data value serving as a criterion for determining whether the nanoparticles 206 are detected by the drug measurement unit 304, is stored. For example, the effective range of the drug delivery device 200 that can effectively act on the affected part 132. [

According to another embodiment of the present invention, it is possible to input intensity of ultrasound and / or light heat according to the drug delivery system 200 to be irradiated with ultrasonic waves and / or light heat. In addition, additional information such as a mechanism of action of the drug delivery device 200 due to the pathology may be input from the external device 110 connected to the drug action management apparatus 100 through the network 120 to update related data from time to time.

According to another embodiment of the present invention, data received from the external device 110 may be automatically updated according to the setting of the user. For example, the user can set the desired time, day, and period. Alternatively, the user can update manually when desired.

The controller 310 controls the ultrasound irradiation unit 302 in response to a user operation or when the result of the drug measurement unit 304 corresponds to a characteristic effective range or pattern of the nanoparticles 206 stored in the memory 308. [ So as to irradiate ultrasonic waves.

According to an embodiment of the present invention, when the amount of measurement of the drug carrier 200 arriving at the affected part 132 is within the effective range stored in the memory 308, control is performed to irradiate ultrasound and / or light .

The operation unit 312 inputs the operation of the user. The operation unit can select the type of the drug delivery device 100 and the type of the nanoparticles 200, and can select a measurement mode or a treatment mode according to a user's operation. The operation unit may be implemented by one or a plurality of buttons. When implemented with one button, it is possible to input a user's operation signal by using the time of pressing the button, the pattern of pressing the button, the tokening method, etc., alone or in combination.

According to an embodiment of the present invention, when the user selects the measurement mode, the degree to which the drug delivery system 100 reaches the affected part can be visually confirmed through the display unit 306. [

According to another embodiment of the present invention, when the user selects the treatment mode, the operation may be input so that the ultrasound and / or light heat may be irradiated according to the drug delivery system 100.

FIG. 4 is a flowchart illustrating a monitoring method using a drug action management apparatus according to an embodiment of the present invention.

In step 400, the drug delivery device 200 is measured near the skin surface or the upper part of the affected part of the affected part based on the characteristics of the nanoparticles 206 contained in the drug delivery device 200. In step 402, it is determined whether the drug delivery device 200 has a predetermined range or pattern and is displayed. In step 404, it is determined whether the result of the measurement of the drug delivery carrier has a predetermined range or pattern in response to a user operation. In step 406, if the measurement result in step 404 has a predetermined range or pattern, ultrasound and / or light heat is controlled to be irradiated to the nanoparticle opening 206a of the drug delivery device 200. [

It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the invention as defined in the appended claims. It will be understood that the invention may be varied and varied without departing from the scope of the invention.

100: drug action management device
102:
104, 106, and 108:
110: External device
130: patient
132:
200: drug delivery vehicle
202: Drugs
204: antibody
206: nanoparticles

Claims (10)

An operation unit for inputting an operation of a user;
An ultrasonic irradiator for irradiating ultrasonic waves;
A drug measurement unit capable of detecting the characteristics of the nanoparticles contained in the drug delivery system;
A display unit capable of visually displaying a result of the drug measurement unit;
A memory in which the characteristic effective range or pattern of the pathology or lesion, nanoparticle is stored; And
A control unit responsive to a user operation or controlling the ultrasonic wave irradiating unit to irradiate the ultrasound wave when the result of the drug measurement unit corresponds to a characteristic effective range or pattern of nanoparticles stored in the memory;
And the drug action management device.
In claim 1,
A communication unit for connecting to an external smart device via a network
Further comprising:
In claim 1,
Wherein the operation unit is capable of selecting a measurement mode and a treatment mode according to an operation of a user.
In claim 1,
The control unit may select the type of the drug delivery system and the type of the nanoparticles. The control unit controls the operation of the ultrasound irradiation unit based on the kind of the drug delivery system selected by the user and the type of the nanoparticle Device.
An operation unit for inputting an operation of a user;
A light irradiation unit for irradiating light;
A drug measurement unit capable of detecting the characteristics of the nanoparticles contained in the drug delivery system;
A display unit capable of visually displaying a result of the drug measurement unit;
A memory in which the characteristic effective range or pattern of the pathology or lesion, nanoparticle is stored; And
A control unit responsive to a user operation or controlling the light irradiation unit to generate light when the result of the drug measurement unit corresponds to a characteristic effective range or pattern of nanoparticles stored in the memory;
And the drug action management device.
In claim 5,
A communication unit for connecting to an external smart device via a network
Further comprising:
In claim 5,
Wherein the operation unit is capable of selecting a measurement mode and a treatment mode according to an operation of a user.
In claim 5,
The control unit may select the kind of the drug delivery vehicle and the kind of the nanoparticle. The control unit controls the operation of the light irradiation unit based on the kind of the drug delivery system selected by the user and the kind of the nanoparticle Device. The method according to any one of claims 5 to 8,
Further comprising an ultrasonic irradiator for irradiating ultrasonic waves.
Measuring the drug delivery system on the skin surface or near the lesion site of the lesion based on the characteristics of the nanoparticles contained in the drug delivery system;
Determining whether the drug delivery vehicle has a predetermined range or pattern and displaying the determined range or pattern;
Controlling the ultrasound or light to be irradiated to the drug carrier in response to a user operation or when the measurement result of the drug carrier has a predetermined range or pattern
≪ / RTI >


KR1020170038755A 2017-03-27 2017-03-27 Device and method for drug action management KR102024273B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020170038755A KR102024273B1 (en) 2017-03-27 2017-03-27 Device and method for drug action management

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170038755A KR102024273B1 (en) 2017-03-27 2017-03-27 Device and method for drug action management

Publications (2)

Publication Number Publication Date
KR20180109327A true KR20180109327A (en) 2018-10-08
KR102024273B1 KR102024273B1 (en) 2019-11-04

Family

ID=63864607

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170038755A KR102024273B1 (en) 2017-03-27 2017-03-27 Device and method for drug action management

Country Status (1)

Country Link
KR (1) KR102024273B1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080002080A (en) * 2006-06-30 2008-01-04 연세대학교 산학협력단 Multi-functional nanoparticles partially-deposited with gold film
JP4927535B2 (en) * 2003-04-03 2012-05-09 ジェシー エル エス オウ Particles encapsulating drugs that target tumors
JP2012532120A (en) 2009-07-01 2012-12-13 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Stimulus-responsive carrier for MPI-induced drug delivery
KR101683463B1 (en) * 2014-12-19 2016-12-08 서울대학교산학협력단 Microbubble-Liposome-Melanine nanoparticle complex and Contrast agent comprising the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4927535B2 (en) * 2003-04-03 2012-05-09 ジェシー エル エス オウ Particles encapsulating drugs that target tumors
KR20080002080A (en) * 2006-06-30 2008-01-04 연세대학교 산학협력단 Multi-functional nanoparticles partially-deposited with gold film
JP2012532120A (en) 2009-07-01 2012-12-13 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Stimulus-responsive carrier for MPI-induced drug delivery
KR101683463B1 (en) * 2014-12-19 2016-12-08 서울대학교산학협력단 Microbubble-Liposome-Melanine nanoparticle complex and Contrast agent comprising the same

Also Published As

Publication number Publication date
KR102024273B1 (en) 2019-11-04

Similar Documents

Publication Publication Date Title
Darweesh et al. Gold nanoparticles and angiogenesis: molecular mechanisms and biomedical applications
Dou et al. To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes
KR101530326B1 (en) Continuous non-interfering health monitoring and alert system
US20100016765A1 (en) Integrated spect imaging and ultrasound therapy system
US11883620B2 (en) Controlled flow drug delivery implantable device
US9125583B2 (en) Detection of cancer with electrical impedance tomography
EP2411067A1 (en) Monitoring of implants and other devices
JP2013501532A (en) Implantable sensor device and pharmaceutical delivery device connectable to such sensor device
WO2016077423A2 (en) Shielded targeting agents, methods, and in vivo diagnostic system
Wu et al. Targeted delivery of engineered auditory sensing protein for ultrasound neuromodulation in the brain
WO2011161562A1 (en) System and method of delivering vestibular stimulation customizable to individual subjects
US20140243737A1 (en) Assays for ultrasound mediated delivery
Martins et al. Nanocomposite hydrogel microneedles: a theranostic toolbox for personalized medicine
KR20180109327A (en) Device and method for drug action management
Volpini et al. The nano-revolution in the diagnosis and treatment of endometriosis
Kim et al. Leveraging translational insights toward precision medicine approaches for brain metastases
CN111920446A (en) System for enhancing medical treatment using ultrasound
CN101378694A (en) Device for monitoring the status of a patient and treatment based thereupon
Colecchia et al. EGFR-targeted magnetic nanovectors recognize, in vivo, head and neck squamous cells carcinoma-derived tumors
Reddy et al. Recent breakthroughs in drug delivery systems for targeted cancer therapy: an overview
US20100256610A1 (en) Apparatus and method of detection and localized treatment of abnormal conditions
WO2013046143A1 (en) Ultrasound mediated delivery with critical-organ protection
Lee Tinnitus retraining therapy
Seale et al. Design of programmable multilayered nanoparticles with in situ manufacture of therapeutic genes for nanomedicine
Turner Detect, Tell, and Treat: Microneedle Skin Patches to Sense and Treat Infection

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant